CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33176
- Center for Excellence in Eye Care
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Stulting Research Center at Woolfson Eye Institute
-
-
Maryland
-
Rockville, Maryland, United States, 20852
- TLC Laser Eye Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02451
- Talamo Hatch Laser Eye Consultants, LLC
-
-
Ohio
-
Brecksville, Ohio, United States, 44141
- Cleveland Eye Clinic
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- TLC Laser Eye Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 8 years of age or older
Having at least one of the following conditions:
- Keratoconus
- Post-LASIK ectasia
- Pellucid marginal degeneration
- Forme fruste pellucid marginal degeneration
- FFKC
- History of Radial Keratotomy with fluctuating vision.
- Terrien's Marginal Degeneration
- Signed written informed consent and/or assent
- Likely to complete all study visits
- Minimum corneal thickness of at least 250 microns measured by ultrasound or Pentacam for all indications other than Terrien's. For Terrien's, the minimal corneal thickness should be consistent with the surgeon's best surgical judgment.
Exclusion Criteria:
- Severe corneal scarring that markedly affects vision
- Contraindications to any study medications or their components
- Pregnancy or breast feeding
- Active Herpes Corneal Disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Theralight crosslinking and Riboflavin
ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using UVA light and the photo- mediator riboflavin
|
Corneal Collagen cross linking with UV light and riboflavin
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Best Spectacle Corrected Visual Acuity (BSCVA)
Time Frame: 6-9 months
|
6-9 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Uncorrected Visual Acuity (UCVA)
Time Frame: 6-9 months
|
6-9 months
|
|
Change in Corneal topography
Time Frame: 6-9 months
|
6-9 months
|
|
Change in Manifest Refraction
Time Frame: 6-9 months
|
6-9 months
|
|
Change in Keratometry on topography and Pentacam
Time Frame: 6-9 months
|
6-9 months
|
|
Change in Wavefront Refraction and aberrations
Time Frame: 6-9 months
|
6-9 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: William Trattler, MD, Cxlusa
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CXL-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.